Pharmaceutical Executive: August 2025

View the Pharmaceutical Executive August 2025 issue in an interactive format.

Spotlighting efforts in precision medicine development, particularly the potential growth of CAR-T therapies in underserved global markets.

Pharm Exec unveils its new slate of rising leaders in the biopharma industry—profiling the stories of five executives steering innovative scientific and strategic pursuits in R&D, market access, and patient support.

Powering learnings of the dark genome to tackle disease at its source.

Pushing for access wins in quickly evolving market and digital health landscapes.

Ex-Wall Street trader is helping reshape how patients receive biologics.

A mission leader in next-generation pursuits around targeted therapy.

Pioneer of cell-reset technology steers science-to-startup transformation.

Why pharma and all stakeholders in the healthcare ecosystem should undertake a fundamental shift in how evidence to support new treatments is generated and assessed.

A look back and ahead at the growing trend—sparked recently by the GLP-1 trail—and new ways to harness this Rx access channel for positive outcomes.

Pharma can embrace product iteration over one-time launches—and enhance agility and responsiveness through effective roadmaps, feedback integration, and communication strategies.

How a layered approach—tapping new avenues from earned media—can go a long way in boosting the brand engagement interplay between pharma companies and physicians.

Strategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful progress in how data insights inform commercial decision-making.

Despite steady innovation and solid new drug approvals, the first half of 2025 was marked by a break from historical norms in financing, stock performance, and M&A for the pharma and biotech sectors.

Challenging six misconceptions that have characterized product strategies in Central and Eastern European markets.

Health plans face challenges in risk arrangements for orphan drugs, but increasing competition may open doors for innovative pricing strategies.

Jeff Liter, CEO of Luminary, discusses his company’s approach to CAR-T therapies and why the developing Saudi market has potential.